Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease

Elissa J. Schwartz, Lynda A. Szczech, Michael J. Ross, Mary E. Klotman, Jonathan A. Winston, Paul E. Klotman

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

The rise in the number of patients with HIV-associated nephropathy and HIV-infection with end-stage renal disease (HIV+ ESRD) continues to be a substantial concern for the ESRD program. In order to assess the impact of highly active antiretroviral therapy (HAART) on the progression of patients with AIDS to the development of ESRD and to project the prevalence of HIV+ ESRD through 2020, a mathematical model of the dynamics of HIV+ infection in the ESRD population was developed. Epidemiologic data on AIDS and HIV+ ESRD among black individuals in the United States were obtained since 1991 from the Centers for Disease Control and Prevention and US Renal Data System, respectively. The model was constructed to predict the prevalence of HIV+ ESRD incorporating the current rate of growth in AIDS prevalence. Two possible trends were considered: linear AIDS growth and exponential AIDS growth. The likely effectiveness of HAART in slowing progression to HIV+ ESRD was estimated from the best fit of the model to the data after 1995, when HAART was introduced. The model was then used to evaluate recent data and to project the prevalence of HIV+ ESRD through 2020. The model suggested that HAART has reduced the rate of progression from AIDS to HIV+ ESRD by 38%. The model projected an increase in HIV+ ESRD prevalence in the future as a result of the increase in the AIDS population among black individuals. This increase was predicted even assuming a 95% reduction in the progression from AIDS to HIV+ ESRD. Despite the potential benefit of HAART, the prevalence of HIV+ ESRD in the United States is expected to rise in the future as a result of the expansion of the AIDS population among black individuals. It is concluded that prevention of progression to ESRD should focus on early antiretroviral treatment of HIV-infected patients who have evidence of HIV-associated nephropathy.

Original languageEnglish (US)
Pages (from-to)2412-2420
Number of pages9
JournalJournal of the American Society of Nephrology
Volume16
Issue number8
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Highly Active Antiretroviral Therapy
Chronic Kidney Failure
HIV
Acquired Immunodeficiency Syndrome
AIDS-Associated Nephropathy
HIV Infections
Growth
Population
Centers for Disease Control and Prevention (U.S.)
Information Systems

ASJC Scopus subject areas

  • Nephrology

Cite this

Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. / Schwartz, Elissa J.; Szczech, Lynda A.; Ross, Michael J.; Klotman, Mary E.; Winston, Jonathan A.; Klotman, Paul E.

In: Journal of the American Society of Nephrology, Vol. 16, No. 8, 2005, p. 2412-2420.

Research output: Contribution to journalArticle

Schwartz, Elissa J. ; Szczech, Lynda A. ; Ross, Michael J. ; Klotman, Mary E. ; Winston, Jonathan A. ; Klotman, Paul E. / Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. In: Journal of the American Society of Nephrology. 2005 ; Vol. 16, No. 8. pp. 2412-2420.
@article{f62c2248804b4e3e88b79163368e6d7e,
title = "Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease",
abstract = "The rise in the number of patients with HIV-associated nephropathy and HIV-infection with end-stage renal disease (HIV+ ESRD) continues to be a substantial concern for the ESRD program. In order to assess the impact of highly active antiretroviral therapy (HAART) on the progression of patients with AIDS to the development of ESRD and to project the prevalence of HIV+ ESRD through 2020, a mathematical model of the dynamics of HIV+ infection in the ESRD population was developed. Epidemiologic data on AIDS and HIV+ ESRD among black individuals in the United States were obtained since 1991 from the Centers for Disease Control and Prevention and US Renal Data System, respectively. The model was constructed to predict the prevalence of HIV+ ESRD incorporating the current rate of growth in AIDS prevalence. Two possible trends were considered: linear AIDS growth and exponential AIDS growth. The likely effectiveness of HAART in slowing progression to HIV+ ESRD was estimated from the best fit of the model to the data after 1995, when HAART was introduced. The model was then used to evaluate recent data and to project the prevalence of HIV+ ESRD through 2020. The model suggested that HAART has reduced the rate of progression from AIDS to HIV+ ESRD by 38{\%}. The model projected an increase in HIV+ ESRD prevalence in the future as a result of the increase in the AIDS population among black individuals. This increase was predicted even assuming a 95{\%} reduction in the progression from AIDS to HIV+ ESRD. Despite the potential benefit of HAART, the prevalence of HIV+ ESRD in the United States is expected to rise in the future as a result of the expansion of the AIDS population among black individuals. It is concluded that prevention of progression to ESRD should focus on early antiretroviral treatment of HIV-infected patients who have evidence of HIV-associated nephropathy.",
author = "Schwartz, {Elissa J.} and Szczech, {Lynda A.} and Ross, {Michael J.} and Klotman, {Mary E.} and Winston, {Jonathan A.} and Klotman, {Paul E.}",
year = "2005",
doi = "10.1681/ASN.2005040340",
language = "English (US)",
volume = "16",
pages = "2412--2420",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "8",

}

TY - JOUR

T1 - Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease

AU - Schwartz, Elissa J.

AU - Szczech, Lynda A.

AU - Ross, Michael J.

AU - Klotman, Mary E.

AU - Winston, Jonathan A.

AU - Klotman, Paul E.

PY - 2005

Y1 - 2005

N2 - The rise in the number of patients with HIV-associated nephropathy and HIV-infection with end-stage renal disease (HIV+ ESRD) continues to be a substantial concern for the ESRD program. In order to assess the impact of highly active antiretroviral therapy (HAART) on the progression of patients with AIDS to the development of ESRD and to project the prevalence of HIV+ ESRD through 2020, a mathematical model of the dynamics of HIV+ infection in the ESRD population was developed. Epidemiologic data on AIDS and HIV+ ESRD among black individuals in the United States were obtained since 1991 from the Centers for Disease Control and Prevention and US Renal Data System, respectively. The model was constructed to predict the prevalence of HIV+ ESRD incorporating the current rate of growth in AIDS prevalence. Two possible trends were considered: linear AIDS growth and exponential AIDS growth. The likely effectiveness of HAART in slowing progression to HIV+ ESRD was estimated from the best fit of the model to the data after 1995, when HAART was introduced. The model was then used to evaluate recent data and to project the prevalence of HIV+ ESRD through 2020. The model suggested that HAART has reduced the rate of progression from AIDS to HIV+ ESRD by 38%. The model projected an increase in HIV+ ESRD prevalence in the future as a result of the increase in the AIDS population among black individuals. This increase was predicted even assuming a 95% reduction in the progression from AIDS to HIV+ ESRD. Despite the potential benefit of HAART, the prevalence of HIV+ ESRD in the United States is expected to rise in the future as a result of the expansion of the AIDS population among black individuals. It is concluded that prevention of progression to ESRD should focus on early antiretroviral treatment of HIV-infected patients who have evidence of HIV-associated nephropathy.

AB - The rise in the number of patients with HIV-associated nephropathy and HIV-infection with end-stage renal disease (HIV+ ESRD) continues to be a substantial concern for the ESRD program. In order to assess the impact of highly active antiretroviral therapy (HAART) on the progression of patients with AIDS to the development of ESRD and to project the prevalence of HIV+ ESRD through 2020, a mathematical model of the dynamics of HIV+ infection in the ESRD population was developed. Epidemiologic data on AIDS and HIV+ ESRD among black individuals in the United States were obtained since 1991 from the Centers for Disease Control and Prevention and US Renal Data System, respectively. The model was constructed to predict the prevalence of HIV+ ESRD incorporating the current rate of growth in AIDS prevalence. Two possible trends were considered: linear AIDS growth and exponential AIDS growth. The likely effectiveness of HAART in slowing progression to HIV+ ESRD was estimated from the best fit of the model to the data after 1995, when HAART was introduced. The model was then used to evaluate recent data and to project the prevalence of HIV+ ESRD through 2020. The model suggested that HAART has reduced the rate of progression from AIDS to HIV+ ESRD by 38%. The model projected an increase in HIV+ ESRD prevalence in the future as a result of the increase in the AIDS population among black individuals. This increase was predicted even assuming a 95% reduction in the progression from AIDS to HIV+ ESRD. Despite the potential benefit of HAART, the prevalence of HIV+ ESRD in the United States is expected to rise in the future as a result of the expansion of the AIDS population among black individuals. It is concluded that prevention of progression to ESRD should focus on early antiretroviral treatment of HIV-infected patients who have evidence of HIV-associated nephropathy.

UR - http://www.scopus.com/inward/record.url?scp=28444460367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444460367&partnerID=8YFLogxK

U2 - 10.1681/ASN.2005040340

DO - 10.1681/ASN.2005040340

M3 - Article

C2 - 15987747

AN - SCOPUS:28444460367

VL - 16

SP - 2412

EP - 2420

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 8

ER -